Hand Foot and Mouth Disease Limited Appeal For Pharmaceutical Investment
This article was originally published in PharmAsia News
Executive Summary
Since early this year, the spread of hand foot and mouth disease in China's Fuyang city and other areas has spurred the sales of domestic antiviral products, drawing the attention of venture capitalists. Several securities companies believe there are investment opportunities, sparking a rise in pharmaceutical shares in recent days. However, analysts caution that such spikes may have close relationship with the Sichuan earthquake. HFMD may drive sales in the short term but has limited impact since the disease is relatively easy to treat. (Click here for more - Chinese Language)
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.